A5084679042- Multiple Sclerosis Research Studies
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Mycobacterium research and diagnosis
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Powdery Mildew Fungal Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- T-cell and Retrovirus Studies
- Retinal and Optic Conditions
- Ophthalmology and Visual Impairment Studies
- Acute Lymphoblastic Leukemia research
- Skin and Cellular Biology Research
- Glaucoma and retinal disorders
- Inflammasome and immune disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Amyotrophic Lateral Sclerosis Research
- Autoimmune and Inflammatory Disorders Research
- Advanced Neuroimaging Techniques and Applications
- Chronic Lymphocytic Leukemia Research
- Intraocular Surgery and Lenses
Karolinska Institutet
2016-2025
Karolinska University Hospital
2015-2025
University of British Columbia
2024
Institute of Neuroimmunology of the Slovak Academy of Sciences
2019-2020
Centre for Palaeogenetics
2020
University Hospital of Basel
2020
University of Gothenburg
2020
University of Basel
2020
Biogen (United States)
2020
Heinrich Heine University Düsseldorf
2020
Abstract Blood Neurofilament light chain (NfL) has been suggested as a promising biomarker in several neurological conditions. Since blood NfL is the consequence of leaked from cerebrospinal fluid, differences individuals’ Body Mass Index (BMI) or volume (BV) might affect its correlation to other biomarkers and disease outcomes. Here, we investigated between plasma NfL, BMI, BV 662 controls 2,586 multiple sclerosis cases. We found significant negative BMI/BV both groups. Our results...
Tobacco smoking has been linked to an increased risk of multiple sclerosis. However, date, results from the few studies on impact progression disability are conflicting. The aim this study was investigate effects and disease severity in a cohort patients with clinically definite We analysed data 895 (270 male, 625 female), mean age 49 years duration 17 years. Forty-nine per cent were regular smokers at time onset or diagnosis (ever-smokers). Average as measured by sclerosis score greater...
<h3>Importance</h3> Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), chronic inflammatory disorder of the central nervous system usually characterized by bouts and remissions typically followed secondary progressive (SP) course. However, it not clear whether smoking after diagnosis detrimental. <h3>Objective</h3> To determine MS associated with change in time to SP disease. <h3>Design, Setting, Participants</h3> Cross-sectional study patients prevalent who...
The aim of this study was to identify factors influencing the long-term clinical progression multiple sclerosis (MS). A special objective investigate whether early treatment decisions influence outcome.We included 639 patients diagnosed with MS from 2001 2007. median follow-up time 99 months (8.25 years). Cox regression models were applied correlating outcome variable defined as start irreversible score 4 Expanded Disability Status Scale (EDSS).Patients initiated on later had a greater risk...
The Multiple Sclerosis Severity Score (MSSS) is obtained by normalising the Expanded Disability Status Scale (EDSS) score for disease duration and has been a valuable tool in cross-sectional studies.To assess whether use of age rather than inherently ambiguous was feasible approach.We pooled disability data from three population-based cohorts developed an Age Related (ARMSS) ranking EDSS scores based on patient's at time assessment. We established power to detect difference between groups...
Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models individual are lacking. Our aims were: (i) to develop algorithms using demographic, clinical and paraclinical predictors patients with (ii) evaluate accuracy, internal external validity these algorithms. This study evaluated 27 seven disease-modifying therapies MSBase, a large global cohort study....
<h3>Objective</h3> To determine factors (including the role of specific disease modulatory treatments [DMTs]) associated with (1) baseline, (2) on-treatment, and (3) change (from treatment start to on-treatment assessment) in plasma neurofilament light chain (pNfL) concentrations relapsing-remitting multiple sclerosis (RRMS). <h3>Methods</h3> Data including blood samples analyses long-term clinical follow-up information for 1,261 Swedish patients RRMS starting novel DMTs were analyzed using...
To evaluate long-term disability progression in pediatric-onset multiple sclerosis (POMS) and compare to adult-onset (AOMS).This was a retrospective cohort study using prospectively collected clinical information from the Swedish MS Registry. Clinical features were compared Kaplan-Meier Cox proportional hazards regression used assess risk of reaching sustained Expanded Disability Status Scale (EDSS) 3, 4, 6 POMS (multiple [MS] onset <18 years) AOMS (MS ≥18 years).A total 12,482 persons...
Cognitive impairment in multiple sclerosis (MS) can lead to reduced quality of life, social functioning, and employment. Few studies have investigated cognitive outcomes among patients with pediatric-onset MS (POMS) over the long term.To compare long-term information-processing efficiency between POMS adult-onset (AOMS).This population-based longitudinal cohort study accessed Swedish Registry (SMSreg), which collates information from all 64 neurology clinics Sweden. Registered cases definite...
Background: Rituximab is a chimeric monoclonal anti-CD20 B-cell-depleting antibody increasingly used off-label in multiple sclerosis (MS). The clinical relevance of anti-drug antibodies (ADAs) against rituximab MS unknown. Objective: To determine frequency ADA relation to B-cell counts, allergic reactions and efficacy large cohort MS-treated patients. Methods: Cross-sectional study with collection serum samples from 339 patients immediately before scheduled infusion. ADAs were detected using...
Depression is common in multiple sclerosis (MS), but its impact on disability worsening has not yet been determined. We explored the risk of associated with depression a nationwide longitudinal cohort.This retrospective cohort study used linked data from 3 Swedish registries: MS Register, National Patient and Prescribed Drug Register. Two incident cohorts were developed: 1 included all registered cases Registry (2001-2014) defined as ≥1 ICD-10 code for depression; 2 comprised (2005-2014)...
To investigate the association between plasma neurofilament light chain (pNfL) levels and risk of developing sustained disability worsening.Concentrations pNfL were determined in 4,385 persons with multiple sclerosis (MS) 1,026 randomly selected population-based sex- age-matched controls using highly sensitive Single Molecule Array (SimoaTM) NF-Light Advantage Kit. We assessed impact age-stratified above 80th, 95th, 99th percentiles among on Expanded Disability Status Scale (EDSS) worsening...
Epstein-Barr virus (EBV) infection has been advocated as a prerequisite for developing multiple sclerosis (MS) and possibly the propagation of disease. However, precise mechanisms such influences are still unclear. A large-scale study investigating host genetics EBV serology related clinical manifestations, infectious mononucleosis (IM), may help us better understand role in MS pathogenesis. This evaluates genetic factors that influence serological response against history IM cross-evaluates...
Abstract Objective Elevated healthcare use before multiple sclerosis (MS) onset suggests earlier opportunity to identify MS. Yet their timing and sociodemographic effects are unclear. We examined rates of (and by age/sex) for >two decades pre‐MS onset. Methods identified people with MS (PwMS) using administrative data from Canada (Ontario) Sweden (1991–2020) (“administrative” cohort), the Swedish Registry (“clinical” cohort). The first MS/demyelinating diagnostic code (administrative) or...
Clinicians' experience and findings from recent natural history studies suggest that multiple sclerosis (MS) may now be running a more slowly progressing course than before.To investigate whether the risk of reaching MS disability milestones has changed over last decade in Sweden.A nationwide population-based retrospective cohort study. By April 2017, 12 512 patients with available information on demographics, phenotype, date onset diagnosis were registered Swedish Registry which 7331 at...
Objectives: We aimed at designing a nomogram, prediction tool, to predict the individual’s risk of conversion secondary progressive multiple sclerosis (SPMS) time (MS) onset. Methods: One derivation and three validation cohorts were established. The cohort included 8825 relapsing-onset MS patients in Sweden. A nomogram was built based on survival model with best statistical fit accuracy. validated using data from 3967 British Columbia cohort, 176 ACROSS 2355 FREEDOMS/FREEDOMS II extension...
Tobacco smoke is an important modifiable environmental risk factor for multiple sclerosis (MS) risk. The population attributable fraction (AF) of MS due to smoking can be used assess the contribution development. We conducted a matched case-control study, including individuals with and population-based controls. Overall, sex- genetic score-stratified AF were calculated by fitting logistic regression models. included 9,419 At time onset 44.1% persons 35.9% controls ever regularly smoked which...
BackgroundAmblyopia, the most common visual impairment of childhood, is a public health concern. An extended period optical treatment before patching recommended by clinical guidelines several countries. The aim this study was to compare an intensive regimen, with and without (EOT), in randomised controlled trial.MethodsEuPatch trial conducted 30 hospitals UK, Greece, Austria, Germany, Switzerland. Children aged 3–8 years newly detected, untreated amblyopia (defined as interocular difference...
Background: The course of multiple sclerosis (MS) has been studied in several cohorts; however, results have varied significantly. Objective: To describe the clinical MS a nationwide cohort patients. Method: Data from Swedish register (SMSreg) were used to estimate median time sustained Expanded Disability Status Scale (EDSS) scores 3.0, 4.0 and 6.0, onset secondary progressive (SPMS) death using Kaplan–Meier method. A possible effect first-line treatments on age at EDSS 6.0 SPMS was...
Background: In multiple sclerosis (MS), various aspects of cognitive function can be detrimentally affected, thus patients’ employment and social functioning is commonly impacted. Objective: To analyse income among MS patients in relation to function, assessed with the Symbol Digit Modalities Test (SDMT). Methods: A cross-sectional study including 2080 was conducted linking national register-based data. Descriptive statistics a two-part model were used estimate differences earnings benefits....
Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years symptom onset. Several clinicodemographic factors have been associated aggressive sclerosis, but less research has focused on clinical markers that are present in first year disease. The development early predictive models is essential to optimize treatment this subtype. We evaluated whether patients who will...